Qiagen (NYSE:QGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.160- for the period, compared to the consensus earnings per share estimate of 2.120. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of 2.160.
Qiagen Trading Down 0.2 %
Qiagen stock traded down $0.09 during trading hours on Friday, reaching $45.42. The company had a trading volume of 847,455 shares, compared to its average volume of 1,245,056. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.45. Qiagen has a 12-month low of $34.74 and a 12-month high of $46.55. The company has a 50-day moving average price of $42.85 and a 200 day moving average price of $43.04. The firm has a market cap of $10.36 billion, a price-to-earnings ratio of 30.46, a P/E/G ratio of 3.19 and a beta of 0.40.
Qiagen (NYSE:QGEN – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million for the quarter, compared to analysts’ expectations of $495.45 million. During the same quarter last year, the business earned $0.53 earnings per share. The business’s revenue was down .2% on a year-over-year basis. Equities analysts forecast that Qiagen will post 2.15 earnings per share for the current year.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on QGEN
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Read More
- Five stocks we like better than Qiagen
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MarketBeat Week in Review – 8/5 – 8/9
- 3 Best Fintech Stocks for a Portfolio Boost
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Stock Market Upgrades: What Are They?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.